- Consolidated revenue increased to $298.0 million for the three months ended September 30, 2016 from $143.0 million for the comparable period of 2015. Consolidated revenue for the nine months ended September 30, 2016 increased to $946.2 million from $215.5 million for the comparable period of 2015.
- Net loss was $15.0 million for the three months ended September 30, 2016 compared to net income of $128.2 million for the comparable period of 2015. For the nine months ended September 30, 2016, net loss was $11.4 million compared to net loss of $31.6 million for the comparable period of 2015
- U.S. commercial launch of RAYALDEE® planned for late November 2016; full marketing and sales team now in place
- Completed acquisition of Transition Therapeutics; Phase 2 clinical trial protocols for two important products being developed
- 4Kscore test utilization continues to grow; many payors now in place, negotiations with others continue
- Topline data for three long acting biologic products to be presented
- Long acting hGH-CTP topline Phase 3 data in adults in 4Q 2016
- Long acting Factor VIIa-CTP safety data from the first in human Phase 2a trial in early 2017
- Long acting oxyntomodulin first in human Phase 1 safety data expected early 2017
- Clinical trials for Claros point of care (POC) PSA test to begin in late 2016; PMA filing anticipated in 1H 2017; Claros POC testosterone test clinical trials and 510(k) filing to follow in 2017
- Consolidated revenues for the three months ended September 30, 2016 increased to $298.0 million from $143.0 million for the comparable period 2015. The 2016 period includes revenue from BioReference, acquired in August 2015.
- Net loss for the three months ended September 30, 2016 was $15.0 million compared with net income of $128.2 million for the 2015 period. Net (loss) income during the three month periods include significant non-recurring and non-cash activities:
- The 2015 period includes a non-recurring income tax benefit related to the release of a valuation allowance against our deferred tax assets as a result of the BioReference acquisition; and
- Other income and (expense) was ($10.5) million and $47.0 million in the 2016 and 2015 periods, respectively, primarily related to the change in fair value of derivative instruments. The change in fair value is principally related to an embedded derivative in OPKO's January 2013 convertible senior notes due in 2033. The 2015 period also includes a non-recurring gain of $17.3 million related to our deconsolidation of SciVac Therapeutics Ltd. The three months ended September 30, 2016 includes $3.9 million of other than temporary impairment expense for two of our strategic investments as a result of a decrease in share price.
- Cash, cash equivalents and marketable securities were $144.6 million as of September 30, 2016.
- RAYALDEE launch scheduled for late November 2016: The U.S. Food and Drug Administration (FDA) approved RAYALDEE for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. RAYALDEE is a patented product containing 30 mcg of a prohormone called calcifediol (25-hydroxyvitamin D3). OPKO has now completed hiring and training a highly specialized marketing and sales team, which is ready for the November 2016 launch .
- Transition Therapeutics: The acquisition of Transition Therapeutics Inc., a Toronto-based biotechnology company, closed in August 2016. Transition Therapeutics has two drugs in mid-stage clinical development; TT401, a long acting GLP-1/glucagon dual agonist for the treatment of type 2 diabetes and obesity, and TT701, an orally administered selective androgen receptor modulator (SARM) being developed for the treatment of patients who will benefit from its effects on increasing muscle and bone strength and decreasing body fat mass.
- 4Kscore test utilization continues to grow; reimbursement in place with many payors, coverage negotiations continue with others: Reimbursement of the 4Kscore test is progressing; pricing agreements are already in place with several payors, and the Company is working to obtain positive coverage by its local Medicare administrator. During the quarter ended September 30, 2016, approximately 16,000 4Kscore tests were performed, a 9% increase from the quarter ended June 30, 2016 and a 365% increase over the comparable period of 2015.
- Topline data for three long acting biologic programs anticipated
- Long acting hGH-CTP topline Phase 3 data in adults in 4Q 2016: OPKO expects to report topline results from its Phase 3 trial evaluating the safety and efficacy of once weekly injections of hGH-CTP with a primary endpoint of superiority compared to placebo in decreasing fat mass in adults with growth hormone deficiency (GHD) in the fourth quarter of 2016. The trial is a randomized, double-blind, placebo controlled, multicenter, global study in adults with GHD.
- Long acting Factor VIIa-CTP safety data from the first in human Phase 2a trial expected in early 2017: This is a dose escalation study to determine safety for OPKO's long-acting version of coagulation Factor VIIa (Factor VIIa-CTP) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.
- Long acting oxyntomodulin first in human Phase 1 safety data expected early 2017: OPKO's Phase 1 single dose escalation study to evaluate the safety and pharmacokinetics of our long acting oxyntomodulin (MOD-6031) in healthy subjects was successful in determining the maximum tolerable dose, indicating activity, as expected.
- Clinical trials for Claros point of care (POC) PSA test to begin in late 2016; PMA filing anticipated in 1H 2017; Claros POC testosterone test clinical trials and 510(k) filing to follow in 2017: OPKO intends to commence a multi-center clinical study of OPKO's POC diagnostic test for prostate specific antigen (PSA) utilizing its proprietary diagnostic platform in late 2016. OPKO intends to submit its application to the FDA for approval of the assay in mid-2017. OPKO expects to commence an additional multi-center clinical study for its POC testosterone test in 2017 followed by a 510(k) submission in late 2017.
"Our BioReference Laboratories and its GeneDx unit continue to grow and the utilization of our innovative 4Kscore test for predicting the probability of aggressive prostate cancer remains strong. Last, we have made great progress on our Claros point of care diagnostic system and anticipate starting clinical trials for our PSA and testosterone tests in the coming months," continued Dr. Frost.CONFERENCE CALL & WEBCAST INFORMATION: OPKO's senior management will provide a business update and discuss results in greater detail in a conference call and live audio webcast at 4:30 p.m. Eastern time today. The conference call dial in information is listed below. To access the webcast, please log on to the OPKO website at www.opko.com. WHEN: Monday, November 7, 2016, 4:30 p.m. ET DOMESTIC DIAL-IN: (866) 634-2258 INTERNATIONAL DIAL-IN: (330) 863-3454 PASSCODE: 12830677 For those unable to participate in the conference call or webcast, a replay will be available beginning November 7, 2016 at 7:30 p.m. ET for a period of time. To access the replay, dial (855) 859-2056 or (404) 537-3406. The replay passcode is: 12830677. The replay can also be accessed for a period of time on OPKO's website at www.opko.com. About OPKO Health, Inc. OPKO Health is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency, VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation PDUFA date: January 2017), TT401, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, and TT701, an androgen receptor modulator for androgen deficiency indications. Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug for hemophilia (in phase 2a) and a long-acting oxyntomodulin for diabetes and obesity (in phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expected financial performance, our product development efforts and the expected benefits of our products, including whether our ongoing and future clinical trials will be completed on a timely basis or at all and whether the data from any of our trials will support approval, validation and/or reimbursement for our products, the expected timing for launch of our products in development, including RAYALDEE, the expected timing of commencing and concluding our clinical trials, enrollment in clinical trials, and disclosure of results for the trials, the timing of our regulatory submissions, our ability to market and sell any of our products in development, expectations about developing RAYALDEE for dialysis patients, our ability to obtain broad reimbursement coverage for the 4Kscore test, increased adoption rates for the 4Kscore, our expectations about the Transition Therapeutics products in development, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission, as well as integration challenges for Bio-Reference, EirGen, Transition, and other acquired businesses, the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results, that the 4Kscore, RAYALDEE, Varubi™, hGH-CTP, and/or any of our compounds or diagnostic products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the indications being studied or for other indications, that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA. CompanyOPKO Health, Inc.Tara Mackay, 305-575-4100Investor Relationsor MediaRooney & AssociatesTerry Rooney, 212-223-0689 firstname.lastname@example.org orMarion Janic, 212-223-4017 email@example.com or InvestorsLHAAnne Marie Fields, 212-838-3777 firstname.lastname@example.org orBruce Voss, 310-691-7100 email@example.com
|OPKO Health, Inc. and Subsidiaries|
|Condensed Consolidated Balance Sheets|
|September 30, 2016||December 31, 2015|
|Cash, cash equivalents and marketable securities||$||144.6||$||193.6|
|Other current assets||357.4||260.5|
|Total Current Assets||502.0||454.1|
|In-process Research and Development and Goodwill||1,347.5||1,535.6|
|Liabilities and Equity:|
|2033 Senior Notes, net||51.5||49.0|
|Deferred tax liabilities||184.5||226.0|
|Other long-term liabilities, principally deferred revenue and contingent consideration||204.1||292.5|
|Total Liabilities and Equity||$||2,800.0||$||2,799.2|
|OPKO Health, Inc. and Subsidiaries|
|Condensed Consolidated Statements of Operations|
|(in millions, except per share data)|
|For the three months ended September 30,||For the nine months ended September 30,|
|Revenue from services||$||259.0||$||103.9||$||777.6||$||107.9|
|Revenue from products||20.6||20.8||63.3||59.1|
|Revenue from transfer of intellectual property||18.4||18.3||105.3||48.5|
|Costs and expenses|
|Cost of revenues||151.2||67.3||452.2||92.1|
|Selling, general and administrative||124.9||55.3||370.3||93.6|
|Research and development||24.4||18.9||83.6||74.0|
|Amortization of intangible assets||18.1||8.1||47.3||14.0|
|Total Costs and expenses||321.7||151.2||969.0||306.1|
|Operating (loss) income||(23.7||)||(8.2||)||(22.8||)||(90.6||)|
|Other income and (expense), net||(10.5||)||47.0||(8.1||)||(23.6||)|
|(Loss) income before income taxes and investment losses||(34.2||)||38.8||(30.9||)||(114.2||)|
|(Provision for) benefit from income taxes||20.0||93.0||24.6||87.2|
|(Loss) income before investment losses||(14.2||)||131.8||(6.3||)||(27.0||)|
|Loss from investments in investees||(0.8||)||(3.6||)||(5.1||)||(6.0||)|
|Net (loss) income||(15.0||)||128.2||(11.4||)||(33.0||)|
|Less: Net loss attributable to non-controlling interests||-||-||-||(1.4||)|
|Net (loss) income attributable to common shareholders||$||(15.0||)||$||128.2||$||(11.4||)||$||(31.6||)|
|Basic income (loss) per share||$||(0.03||)||$||0.26||$||(0.02||)||$||(0.07||)|
|Diluted income (loss) per share||$||(0.03||)||$||0.18||$||(0.02||)||$||(0.07||)|